EP Wealth Advisors LLC Acquires 97,152 Shares of Johnson & Johnson $JNJ

Key Points

• EP Wealth Advisors increased its Johnson & Johnson stake by 15.9% in the second quarter, adding 97,152 shares to own 708,767 shares valued at approximately $180 million. Institutional investors collectively own 69.55% of JNJ.
• Analyst sentiment remains favorable, with JNJ carrying a consensus rating of “Moderate Buy” and an average price target of $272.83, although ratings range from “Strong Buy” to “Hold.” The stock recently traded at $275.63, near its 52-week high of $281.07.
• Johnson & Johnson beat quarterly expectations with adjusted EPS of $2.90 and revenue of $25.31 billion, up 6.6% year over year. The company also declared a quarterly dividend of $1.34, while insiders have sold nearly $16.25 million in shares over the past 90 days.

EP Wealth Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 708,767 shares of the company's stock after purchasing an additional 97,152 shares during the period. Johnson & Johnson makes up about 0.7% of EP Wealth Advisors LLC's holdings, making the stock its 25th biggest position. EP Wealth Advisors LLC's holdings in Johnson & Johnson were worth $180,006,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank lifted its position in Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC raised its stake in Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after buying an additional 692 shares during the last quarter. Wealth Group Ltd. grew its position in Johnson & Johnson by 12.8% during the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock valued at $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. raised its stake in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after purchasing an additional 6,584 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on JNJ. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Leerink Partners upgraded Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price target for the company in a report on Wednesday, May 13th. Finally, Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $272.83.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the business's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 63,972 shares of company stock valued at $16,245,605. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $275.63 on Thursday. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The stock has a market capitalization of $664.25 billion, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 2.59 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a 50-day simple moving average of $260.90 and a 200-day simple moving average of $244.61.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the previous year, the firm earned $2.77 EPS. The business's revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson's payout ratio is presently 62.11%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: UBS initiated coverage of Johnson & Johnson (JNJ) with a Buy rating and a $320 target, reflecting expectations that the company’s pharmaceutical pipeline can support stronger growth. J&J Jumps as UBS Lifts Its Target to $320
• Positive Sentiment: Healthcare stocks broadly moved higher, with the NYSE Healthcare Index gaining 0.7%, creating a favorable backdrop for JNJ and other defensive healthcare names. Sector Update: Healthcare Stocks Advance Wednesday
• Positive Sentiment: Management will participate in a Deutsche Bank Healthcare Summit fireside chat on September 17. The event could provide additional commentary on the drug pipeline, growth outlook and capital allocation, although no new financial guidance was announced. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source